Amgen and Adaptive Biotechnologies will work together to identify and develop an antibody therapy for COVID-19. Adaptive aims to screen tens of thousands of antibodies produced by B cells in people who have recovered from COVID-19 and find ones that neutralize the virus that causes it, SARS-CoV-2. Amgen will develop and manufacture the best antibodies to test as therapies. Adaptive is also expandinga collaboration with Microsoft to study how T cells respond to the viral infection.
C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.